Aprea Therapeutics Inc (APRE NASDAQ) stock market data APIs
$0.8388
-0.03(-3.6%)
as of May 4, 2026
Try our APIs with
free plan!
Aprea Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
Prev. Close
0.8388
Open
0.8096
High
0.8444
Low
0.8054
52 wk Range
0.548-2.22
Market Cap
9 802 K
Shares Outstanding
11 983 K
Revenue
286 K
EPS
-0.32
Beta
1.52
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Aprea Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Aprea Therapeutics Inc data using free add-ons & libraries
Get Aprea Therapeutics Inc Fundamental Data
Aprea Therapeutics Inc Fundamental data includes:
- Net Revenue: 286 K
- EBITDA: -13 212 121
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-16
- EPS/Forecast: -0.36
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Aprea Therapeutics Inc News
New
Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting
DOYLESTOWN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the d...
Aprea Therapeutics Closes Oversubscribed $30 Mln Private Placement; Stock Down
(RTTNews) - Aprea Therapeutics, Inc. (APRE), a clinical-stage precision medicine oncology company, on Wednesday announced the closing of its previously announced oversubscribed $30 million private pla...
Aprea Therapeutics GAAP EPS of -$0.32 beats by $0.07
* Aprea Therapeutics press release [https://seekingalpha.com/pr/20438259-aprea-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-a] (APRE [https://seekingalpha.co...
Most and least shorted healthcare stocks with up to $2B market cap
Short interest in small-cap healthcare surged toward the end of January, centering heavily on the biotechnology sector. Data as of January 30 shows that KalVista (KALV [https://seekingalpha.com/symbol...
Get Aprea Therapeutics Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
